JRP
JNCE

Jasper Ridge Partners’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Jasper Ridge Partners’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50,858
Closed -$378K – 153
2021
Q3 		$378K Buy
+50,858
New +$315K 0.02% 130

Other funds holding JNCE

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Jasper Ridge Partners's JNCE Position: Q4 2021 in Review

Jasper Ridge Partners sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2021, closing a stake of 50,858 shares — an estimated $378K sold.

Jasper Ridge Partners first reported a position in JNCE in Q3 2021 and held it in 1 quarter. The position peaked at $378K in Q3 2021. 124 funds tracked by Wall St. Rank hold JNCE as of Q4 2021.

  • Jasper Ridge Partners reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Jasper Ridge Partners sold 50,858 Jounce Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $378K.
  • Jasper Ridge Partners first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Jasper Ridge Partners's Jounce Therapeutics, Inc. Common Stock position peaked at $378K in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Jasper Ridge Partners's 13F filing for Q4 2021, filed 11 Feb 2022.